Maintaining persistence and adherence with subcutaneous growth-hormone therapy in children: comparing jet-delivery

Helen A Spoudeas1, Priti Bajaj2, Nathan Sommerford3

  • 1London Centre for Paediatric Endocrinology, University College London, London, UK.

Insights

The ZomaJet jet-delivery device significantly improved persistence and adherence in children receiving growth hormone (GH) therapy compared to traditional needle-based devices. Offering jet-delivery options may enhance treatment outcomes.

Area of Science:

  • Pediatric endocrinology
  • Pharmacotherapy adherence
  • Medical device technology

Background:

  • Subcutaneous growth hormone (GH) therapy in children often suffers from suboptimal persistence and adherence.
  • Needle-based delivery devices are the conventional method for administering GH.

Purpose of the Study:

  • To evaluate the impact of the ZomaJet jet-delivery device on medication-taking behaviors in children undergoing GH therapy.
  • To compare the persistence and adherence rates between ZomaJet and traditional needle-based GH delivery devices.

Main Methods:

  • Retrospective cohort study utilizing a UK nationwide database of GH home-delivery schedules (2010-2012).
  • Analysis included 6,061 children (≤18 years) receiving somatropin via ZomaJet or six needle-based GH brands.
  • Persistence measured by time between first and last home deliveries; adherence analyzed by proportion of days covered for ZomaJet users.

Main Results:

  • Significantly longer persistence with GH therapy was observed in ZomaJet users (599 days) compared to needle-based devices (535 days; P<0.001).
  • The majority of ZomaJet patients (58%) were adherent; only 5% of all patients switched GH brands.
  • ZomaJet users tended to use the device for longer durations before considering a switch.

Conclusions:

  • Jet-delivery devices, such as ZomaJet, may be a crucial strategy for improving persistence in pediatric GH therapy.
  • Offering jet-delivery devices could lead to better clinical outcomes and cost-efficiency in managing childhood GH deficiency.
  • The choice of delivery device significantly influences patient adherence and long-term treatment success.
Abstract

Related Concept Videos

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
200
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
521
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
2.8K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.1K
Routes of Drug Administration: Parenteral01:25

Routes of Drug Administration: Parenteral

The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
3.6K